3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Other solid neoplasm
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Mesothelioma, Malignant
5
Unspecified Adult Solid Tumor, Protocol Specific
3
Solid Tumor, Adult
3
Solid Tumor
2
Pleural Effusion, Malignant
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Skin Neoplasms
1
Select Advanced Solid Tumors
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Disease Progression
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Advanced Solid Tumors
1
Advanced Refractory Solid Tumors
1
Advanced Malignant Solid Tumor
1
Interventions
pembrolizumab
5
Nivolumab
2
Ipilimumab
2
obinutuzumab
1
naptumomab estafenatox
1
epacadostat
1
enzalutamide
1
entinostat
1
durvalumab
1
PM 01183
1
Megestrol Acetate
1
Levoleucovorin
1
Leucovorin
1
Irinotecan
1
Interleukin-2
1
Fentanyl
1
Docetaxel
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Interleukin-2
×
Other solid neoplasm
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled